Perinatal outcomes in indian women with Antiphospholipid Antibody Syndrome (APS): Five year experience from a tertiary care centre

IF 1.5 Q3 OBSTETRICS & GYNECOLOGY
Minakshi Rohilla, Mahak Bhardwaj, Vanita Jain
{"title":"Perinatal outcomes in indian women with Antiphospholipid Antibody Syndrome (APS): Five year experience from a tertiary care centre","authors":"Minakshi Rohilla,&nbsp;Mahak Bhardwaj,&nbsp;Vanita Jain","doi":"10.1016/j.eurox.2024.100340","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Antiphospholipid Syndrome (APS) is a systemic autoimmune thrombophilic condition characterized by obstetric manifestations, including pregnancy loss, preeclampsia and fetal growth restriction. Early diagnosis and management are key to improve maternal and neonatal outcomes.</p></div><div><h3>Objective</h3><p>The aim of this study is to assess the perinatal outcomes in APS, the development of various adverse pregnancy outcomes (APO), and their association with specific antibody profiles.</p></div><div><h3>Material methods</h3><p>This observational study was carried out on booked cases of singleton pregnancy and diagnosed cases of primary APS in our High-Risk Pregnancy (HRP) clinic from January 2018 to December 2022 after approval from institutional ethics committee. Forty-three confirmed cases of primary APS were enrolled and started on low-dose aspirin and low-molecular-weight heparin (LMWH) as per the patient's body weight after confirmation of fetal heart activity radiologically until 36 weeks of gestation as a standard of care.</p></div><div><h3>Results</h3><p>Forty patients (93 %) had obstetric APS, and three patients (7 %) had thrombotic APS. During the course of the current pregnancy, adverse pregnancy outcomes (APO) developed in 12 (30 %) out of 40 cases of obstetric APS and in all 3 patients with thrombotic APS. Preeclampsia was seen in 11 (25.5 %), FGR in 12 (27.9 %), and preterm birth in 7 (16.2 %) cases. Patients with an antibody profile showing the presence of Anti-β2 GP-I positivity and ACL positivity had fewer APOs (20 % and 29 %) in comparison to patients with a LA and triple positive antibody profile (55 % and 50 %).</p></div><div><h3>Conclusion</h3><p>Treatment of pregnant women with APS causes significant improvement in the live birth rate. The late pregnancy complications like preeclampsia, FGR, and premature birth, occurring despite treatment still remains a challenge and emphasizes the need for stringent antepartum surveillance and timely delivery.</p></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590161324000607/pdfft?md5=85d7e3293ae8c9dc7dc60408a7453e24&pid=1-s2.0-S2590161324000607-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590161324000607","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Antiphospholipid Syndrome (APS) is a systemic autoimmune thrombophilic condition characterized by obstetric manifestations, including pregnancy loss, preeclampsia and fetal growth restriction. Early diagnosis and management are key to improve maternal and neonatal outcomes.

Objective

The aim of this study is to assess the perinatal outcomes in APS, the development of various adverse pregnancy outcomes (APO), and their association with specific antibody profiles.

Material methods

This observational study was carried out on booked cases of singleton pregnancy and diagnosed cases of primary APS in our High-Risk Pregnancy (HRP) clinic from January 2018 to December 2022 after approval from institutional ethics committee. Forty-three confirmed cases of primary APS were enrolled and started on low-dose aspirin and low-molecular-weight heparin (LMWH) as per the patient's body weight after confirmation of fetal heart activity radiologically until 36 weeks of gestation as a standard of care.

Results

Forty patients (93 %) had obstetric APS, and three patients (7 %) had thrombotic APS. During the course of the current pregnancy, adverse pregnancy outcomes (APO) developed in 12 (30 %) out of 40 cases of obstetric APS and in all 3 patients with thrombotic APS. Preeclampsia was seen in 11 (25.5 %), FGR in 12 (27.9 %), and preterm birth in 7 (16.2 %) cases. Patients with an antibody profile showing the presence of Anti-β2 GP-I positivity and ACL positivity had fewer APOs (20 % and 29 %) in comparison to patients with a LA and triple positive antibody profile (55 % and 50 %).

Conclusion

Treatment of pregnant women with APS causes significant improvement in the live birth rate. The late pregnancy complications like preeclampsia, FGR, and premature birth, occurring despite treatment still remains a challenge and emphasizes the need for stringent antepartum surveillance and timely delivery.

患有抗磷脂抗体综合征(APS)的印度妇女的围产期结局:一家三级医疗中心的五年经验
背景抗磷脂综合征(APS)是一种全身性自身免疫性嗜血栓性疾病,以产科表现为特征,包括妊娠失败、子痫前期和胎儿生长受限。本研究旨在评估 APS 的围产期结局、各种不良妊娠结局(APO)的发生及其与特异性抗体谱的相关性。材料方法本观察性研究于 2018 年 1 月至 2022 年 12 月期间,经机构伦理委员会批准,在我院高危妊娠(HRP)门诊对预订的单胎妊娠病例和确诊的原发性 APS 病例进行了研究。43例确诊的原发性APS病例入选,在放射学上确认胎儿心脏活动后,根据患者体重开始服用小剂量阿司匹林和低分子量肝素(LMWH),作为标准护理直至妊娠36周。结果40例患者(93%)患有产科APS,3例患者(7%)患有血栓性APS。在本次妊娠过程中,40 例产科 APS 中的 12 例(30%)和所有 3 例血栓性 APS 患者都出现了不良妊娠结局(APO)。其中 11 例(25.5%)出现子痫前期,12 例(27.9%)出现胎儿畸形,7 例(16.2%)出现早产。抗体图谱显示抗β2 GP-I 阳性和 ACL 阳性的患者与 LA 和三重抗体图谱阳性的患者(55% 和 50%)相比,APO 的比例较低(20% 和 29%)。尽管进行了治疗,但子痫前期、胎儿畸形和早产等妊娠晚期并发症的发生仍是一个挑战,这也强调了严格产前监测和及时分娩的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
0.00%
发文量
31
审稿时长
58 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信